C4 Therapeutics (CCCC) News Today $2.37 -0.11 (-4.44%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$2.43 +0.06 (+2.53%) As of 10/17/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CCCC Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period C4 Therapeutics prices $125M underwritten offeringOctober 16, 2025 | msn.comC4 Therapeutics, Inc. Announces $125 Million Underwritten Offering to Advance Cemsidomide Multiple Myeloma DevelopmentOctober 16, 2025 | quiverquant.comQC4 Therapeutics Announces Pricing of $125 Million Underwritten OfferingOctober 16, 2025 | globenewswire.comC4 Therapeutics (NASDAQ:CCCC) Receives "Sell (D-)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comC4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed ...October 1, 2025 | markets.businessinsider.comC4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple MyelomaOctober 1, 2025 | globenewswire.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 29, 2025 | marketbeat.comC4 Therapeutics price target raised to $10 from $8 at BarclaysSeptember 22, 2025 | msn.comForecasting The Future: 4 Analyst Projections For C4 TherapeuticsSeptember 22, 2025 | benzinga.comC4 Therapeutics' (CCCC) Overweight Rating Reiterated at StephensSeptember 22, 2025 | marketbeat.comC4 Therapeutics, Inc. - Special CallSeptember 22, 2025 | seekingalpha.comC4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual MeetingSeptember 20, 2025 | globenewswire.comC4 Therapeutics (NASDAQ:CCCC) Stock Rating Upgraded by BarclaysSeptember 19, 2025 | marketbeat.comC4 Therapeutics (CCCC): Evaluating Valuation After Analyst Upgrade and Pipeline DevelopmentsSeptember 18, 2025 | finance.yahoo.comC4 Therapeutics (NASDAQ:CCCC) Coverage Initiated at BarclaysSeptember 18, 2025 | marketbeat.comBarclays Initiates Coverage of C4 Therapeutics (CCCC) with Overweight RecommendationSeptember 17, 2025 | msn.comC4 Therapeutics initiated with an Overweight at BarclaysSeptember 16, 2025 | msn.comDoes FDA Progress Reinforce C4 Therapeutics' (CCCC) Platform Validation Story in Autoimmune Disease?September 16, 2025 | finance.yahoo.comStephens Upgrades C4 Therapeutics (NASDAQ:CCCC) to "Overweight"September 16, 2025 | marketbeat.comStephens & Co. Upgrades C4 Therapeutics (CCCC)September 16, 2025 | msn.comC4 Therapeutics jumps after Stephens upgrade points to upside potentialSeptember 16, 2025 | msn.comC4 Therapeutics jumps after Stephens upgrade points to upside potentialSeptember 16, 2025 | msn.comC4 Therapeutics stock surges after Stephens upgrade signals upsideSeptember 15, 2025 | za.investing.comJacobs Levy Equity Management Inc. Purchases Shares of 697,653 C4 Therapeutics, Inc. $CCCCSeptember 14, 2025 | marketbeat.comNuveen LLC Purchases Shares of 192,424 C4 Therapeutics, Inc. $CCCCSeptember 8, 2025 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of "Hold" by BrokeragesSeptember 6, 2025 | marketbeat.comGuggenheim Initiates Coverage of C4 Therapeutics (CCCC) with Buy RecommendationSeptember 5, 2025 | msn.comC4 Therapeutics announces Biogen had its IND for BIIB142 accepted by FDASeptember 4, 2025 | msn.comC4 Therapeutics Highlights Recent Achievement in Biogen CollaborationSeptember 4, 2025 | globenewswire.comC4 Therapeutics initiated with a Buy at GuggenheimSeptember 4, 2025 | msn.comC4 Therapeutics to present data from Phase 1 trial of cemsidomideSeptember 3, 2025 | msn.comC4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual MeetingSeptember 3, 2025 | globenewswire.comFY2028 EPS Forecast for C4 Therapeutics Lowered by AnalystAugust 12, 2025 | marketbeat.comCCCC Revenue Drops 46%August 12, 2025 | theglobeandmail.comWall Street Zen Downgrades C4 Therapeutics (NASDAQ:CCCC) to SellAugust 10, 2025 | marketbeat.comC4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 7, 2025 | globenewswire.comC4 Therapeutics (CCCC) Expected to Announce Quarterly Earnings on ThursdayJuly 31, 2025 | marketbeat.comC4 Therapeutics (NASDAQ:CCCC) Stock Price Up 7.9% - Here's WhyJuly 18, 2025 | marketbeat.comSG Americas Securities LLC Buys Shares of 425,096 C4 Therapeutics, Inc. (NASDAQ:CCCC)June 21, 2025 | marketbeat.comC4 Therapeutics: An Entry Point If There's Ever Going To Be OneJune 16, 2025 | seekingalpha.comMillennium Management LLC Has $1.30 Million Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC)June 5, 2025 | marketbeat.comTwo Sigma Investments LP Cuts Position in C4 Therapeutics, Inc. (NASDAQ:CCCC)June 2, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 181,200 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)May 28, 2025 | marketbeat.comBank of America Corp DE Reduces Stake in C4 Therapeutics, Inc. (NASDAQ:CCCC)May 28, 2025 | marketbeat.comSoleus Capital Management L.P. Has $25.12 Million Stock Position in C4 Therapeutics, Inc. (NASDAQ:CCCC)May 21, 2025 | marketbeat.comTang Capital Management LLC Boosts Stock Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC)May 20, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 353,861 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)May 20, 2025 | marketbeat.comQ2 EPS Estimates for C4 Therapeutics Decreased by AnalystMay 13, 2025 | marketbeat.comC4 Therapeutics (CCCC) Expected to Announce Earnings on WednesdayMay 9, 2025 | marketbeat.comMarshall Wace LLP Has $130,000 Stock Position in C4 Therapeutics, Inc. (NASDAQ:CCCC)May 9, 2025 | marketbeat.com Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CCCC Media Mentions By Week CCCC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CCCC News Sentiment▼0.660.49▲Average Medical News Sentiment CCCC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CCCC Articles This Week▼32▲CCCC Articles Average Week Get the Latest News and Ratings for CCCC and Related Stocks Enter your email address to receive the latest news and analysts' ratings for C4 Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Keros Therapeutics News Today MeiraGTx News Today Kodiak Sciences News Today Monte Rosa Therapeutics News Today Zevra Therapeutics News Today COMPASS Pathways News Today Niagen Bioscience News Today Siga Technologies News Today Compass Therapeutics News Today Opthea News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CCCC) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
